Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Apr 1.

Published in final edited form as: Shock. 2018 Apr;49(4):412–419. doi: 10.1097/SHK.0000000000000997

Temporal changes in serum concentrations of 14:0–24:1 fatty acids in L-carnitine- and placebo-treated patients, stratified by survival (A–W). While L-carnitine treated, non-survivors demonstrated trends towards having higher levels of various long-chain (C14–C21) and very long-chain fatty acids than survivors [(C) 16:0, (G) 18:1(n-9), (K) 20:0 (Q) 22:0, (R) 22:1, and (V) 24:0], prior to and following [(J) 18:3(n-6), (P) 20:5, (Q) 22:0, and (W) 24:1] carnitine administration, no clear and consistent trend or single biochemical pathway appeared to be implicated as specifically impaired or altered. In placebo-treated patients, the findings were less remarkable in that there were no differences or trends in FA profiles between survivors and non-survivors.

Temporal changes in serum concentrations of 14:0–24:1 fatty acids in L-carnitine- and placebo-treated patients, stratified by survival (A–W). While L-carnitine treated, non-survivors demonstrated trends towards having higher levels of various long-chain (C14–C21) and very long-chain fatty acids than survivors [(C) 16:0, (G) 18:1(n-9), (K) 20:0 (Q) 22:0, (R) 22:1, and (V) 24:0], prior to and following [(J) 18:3(n-6), (P) 20:5, (Q) 22:0, and (W) 24:1] carnitine administration, no clear and consistent trend or single biochemical pathway appeared to be implicated as specifically impaired or altered. In placebo-treated patients, the findings were less remarkable in that there were no differences or trends in FA profiles between survivors and non-survivors.